On Tuesday, Johnson & Johnson (NYSE:JNJ) reported a third-quarter adjusted EPS of $2.42, down 9.0% year-over-year, beating the consensus of $2.21. The pharmaceutical giant reported sales of $22.47 billion, up 5.2% year over year and beating the consensus of $22.16 billion.
Operational growth was 6.3%, and adjusted operational growth was 5.4%.
Innovative Medicine sales increased to $14.58 billion, up 4.9% (+6.3% adjusted operational). Growth was driven by Darzalex (daratumumab), Erleada (apalutamide), Carvykti (ciltacabtagene autoleucel), Tremfya (guselkumab), Spravato (esketamine), and Opsumit (macitentan).
Stelara (ustekinumab) and Simponi/Simponi ARIA (golimumab)partially offset growth.
Also Read: More Patients On Eli Lilly’s Mirikizumab Achieved Histologic Response At One Year Compared To Johnson & Johnson’s Drug
Stelara sales fell 5.7% ...
